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Background: Alzheimer’s disease (AD) is a progressive brain disease, for which there is no effective drug
therapy at present. Ginsenoside Rg1 (G-Rg1) and G-Rg2 have been reported to alleviate memory dete-
rioration. However, the mechanism of their anti-AD effect has not yet been clearly elucidated.
Methods: Ultra performance liquid chromatography tandem MS (UPLC/MS)-based metabolomics was
used to identify metabolites that are differentially expressed in the brains of AD mice with or without
ginsenoside treatment. The cognitive function of mice and pathological changes in the brain were also
assessed using the Morris water maze (MWM) and immunohistochemistry, respectively.
Results: The impaired cognitive function and increased hippocampal Ab deposition in AD mice were
ameliorated by G-Rg1 and G-Rg2. In addition, a total of 11 potential biomarkers that are associated with
the metabolism of lysophosphatidylcholines (LPCs), hypoxanthine, and sphingolipids were identiﬁed in
the brains of AD mice and their levels were partly restored after treatment with G-Rg1 and G-Rg2. G-Rg1
and G-Rg2 treatment inﬂuenced the levels of hypoxanthine, dihydrosphingosine, hexadecasphinganine,
LPC C 16:0, and LPC C 18:0 in AD mice. Additionally, G-Rg1 treatment also inﬂuenced the levels of
phytosphingosine, LPC C 13:0, LPC C 15:0, LPC C 18:1, and LPC C 18:3 in AD mice.
Conclusion: These results indicate that the improvements in cognitive function andmorphological changes
produced by G-Rg1 and G-Rg2 treatment are caused by regulation of related brain metabolic pathways.
This will extend our understanding of the mechanisms involved in the effects of G-Rg1 and G-Rg2 on AD.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer’s disease (AD) is an irreversible, progressive brain
disease and one of the most debilitating neurodegenerative dis-
eases in aging populations. As a type of dementia, it causes prob-
lems with memory, thinking, and behavior [1]. Worldwide, 36
million people suffer from dementia with numbers forecast to
reach 80 million by 2040 [2]. Although AD is a major global public
health problem, the actual biochemical basis for neuro-
degeneration is still poorly understood, and there are few treat-
ments available to slow or stop the deterioration of brain cells [3].
Therefore, the development of potential therapeutic agents that can
prevent or retard AD-related memory decline and studies of their
effects on the brains of AD patients are urgently needed.ospital, China Medical University, N
ht  2015, The Korean Society of G
c-nd/4.0/).Ginseng, as a herbal medicine, has long been used to alleviate
many ailments, particularly those associated with aging and
memory deterioration [4,5]. Ginseng produces its effects at multi-
ple sites of action, whichmakes it an ideal candidate for developing
multitarget drugs. This is most important in AD where multiple
etiological and pathological factors work together to regulate the
ﬁnal pathophysiology of the disease [6e8]. Therefore, ginseng and
ginsenosides are increasingly attracting attention because of their
neuroprotective properties. Previous pathological studies have re-
ported that Ginsenoside Rg1 (G-Rg1) displays promising effects by
reducing cerebral Ab levels and reversing certain neuropathological
changes [9,10]. G-Rg2 has been reported to exert a neuroprotective
effect against glutamate-induced neurotoxicity in PC12 cells [11].
However, previous studies have mainly focused on the biochemicalo. 36, Sanhao Street, Heping District, Shenyang, Liaoning Province, China.
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examined the changes in metabolite proﬁles that occur upon
treatment with G-Rg1 and G-Rg2.
Metabolomics is deﬁned as “a quantitative measurement of
multi-parametric metabolic responses of multi-cellular systems to
pathophysiological stimuli or genetic signaling” [12]. As an
important component of systems biology, metabolomics can pro-
vide a comprehensive systems-level study of the relationships be-
tween metabolites, disease, and drugs [13]. Ultra performance
liquid chromatography tandem MS (UPLC/MS), which is an estab-
lished technology in metabolomics research, has main advantages
including awide dynamic range, reproducible quantitative analysis,
and the ability to analyze bioﬂuids with extreme molecular
complexity [14,15]. As a global biochemical approach to biomarker
discovery, UPLC/MS has recently been applied to the study of a
number ofmetabolic and neurodegenerative diseases [16,17]. In our
previous studies, UPLC/MS was used to determine changes in
metabolite levels in the plasma of AD patients [18,19]. Those studies
provided preliminary basics for the study of drug effects on AD
using metabolomics.
The aim of this studywas to investigate themetabolic changes in
the brains of G-Rg1 and G-Rg2 treated APP/PS1 transgenic mice. In
addition, the Morris water maze (MWM) test and immunohisto-
chemistrywere used to assess the effects of G-Rg1 andG-Rg2 on the
cognitive function and pathological changes in APP/PS1mice. To our
knowledge, this is the ﬁrst report of the use of a UPLC/MS-based
brain tissue metabolomics method to investigate the interven-
tional effects of G-Rg1 and G-Rg2 on AD, which may facilitate our
understanding of the anti-AD mechanism of these ginsenosides.
2. Materials and methods
2.1. Materials
Acetonitrile (HPLC grade) and methanol (HPLC grade) were
purchased from Fisher Scientiﬁc (Fair Lawn, NJ, USA). Formic acid
(HPLC grade) was obtained from Kermel Industrial (Tianjin, China).
G-Rg1 and G-Rg2 (purity  98%) were purchased from Shanghai
Yuanye Bio-Technology Co., Ltd (Shanghai, China). The reference
standards (purity  98%) of hypoxanthine, hexadecasphinganine,
dihydrosphingosine, phytosphingosine, lysophosphatidylcholine
(LPC) C 13:0, LPC C 15:1, LPC C 15:0, LPC C 16:0, LPC C 18:3, LPC C
18:1, and LPC C 18:0 were obtained from the National Standard
Substances Center (Beijing, China). Distilled water, prepared from
demineralized water, was used throughout the experiments.
2.2. Animal handling and sample collection
Male APP/PS1 mice (No. 11401300006401), weighing 20  2 g,
and male C57BL/6J mice (No. 11401300006402), weighing 20  2 g,
were supplied by Beijing HFK Bio-Technology Co., Ltd (Beijing,
China). The animals were genotyped by polymerase chain reaction
analysis of the DNA extracted from tail biopsies. The animals, aged 7
mo, were maintained in an air-conditioned animal center at
23  2C and a relative humidity of 50  10%, with a natural light-
dark cycle. Food and water were available ad libitum. After accli-
matization for 1 wk, the mice were divided into four groups (n¼ 10
in each group): the normal control group, the AD model group, the
G-Rg1 group, and the G-Rg2 group. According to the concentration-
response curves, the mice in the G-Rg1 and G-Rg2 groups were
injected intraperitoneally once daily with G-Rg1 and G-Rg2 (30 mg/
kg), respectively, dissolved in saline. The mice in the AD model
group (APP/PS1 mice) and the normal control group (C57BL/6J
nontransgenic littermates) were treated with isodose saline (0.9%
w/v). All mice were treated for 1 mo before brain metaboliteproﬁling. Experiments were conducted in accordance with the
regulations for animal experimentation issued by the State Com-
mittee of Science and Technology of China.
2.3. MWM
Spatial learning and memory were tested with the MWM test
[20,21]. A circular water tank (diameter  height, 120 cm  40 cm)
was ﬁlled with water at 23  2C and divided into four equal quad-
rants. The water was made opaque by the addition of white nontoxic
water-soluble paint. A submerged platform (diameter  height,
8 cm 10 cm)painted blackwas centered in the fourthquadrant 1 cm
below thewater surface. A camera placed 2 m above the center of the
tank recorded escape latencies during each trial. The chamber con-
tained a number ofﬁxed visual cues on thewalls. The place navigation
test was performed twice daily for 5 d. Mice were trained to ﬁnd and
escapeonto theﬁxedplatform fromdifferent startingpositionswithin
60 s;whenmice failed to locate the platform, theywere gently guided
and allowed to remain on it for 10 s before being returned to their
cage. The average escape latencyof eachmousewas calculated.On the
day after the place navigation test, the spatial exploration test was
conducted for which the platform was removed. The time spent
swimming in the target quadrant and the number of crossings of the
previous platform site were determined for each mouse.
2.4. Immunohistochemistry
Immunohistochemistry was used to evaluate the histopatho-
logical changes in the brains of the mice [22]. Mice were deeply
anesthetizedwith 7% choral hydrate and their brainswere removed
and ﬁxed in 4% paraformaldehyde, embedded in parafﬁn, and
sectioned at a thickness of 4 mm. After deparafﬁnization in xylene
and rehydration in a graded alcohol series, sections were incubated
in3%hydrogenperoxide at 37C for 10 min to inactivateendogenous
peroxidase. Antigen retrieval was performed by boiling sections in
0.01Mcitratebuffer (pH6.0) for 5 minandblockingwithgoat serum.
Ab deposits were detected with mouse anti-Ab antibody (6E10;
Covance,Dedham,MA,USA)diluted1:200at4Covernight. Sections
were washed with 0.01M phosphate-buffered saline, and then
incubatedwithbiotin-conjugatedgoat anti-mouse immunoglobulin
G (1:500; Sigma-Aldrich, St. Louis,MO,USA)at 30C for30 min.After
washing, horseradish peroxidase-labeled streptomycin-avidin
working solution was added to the sections, which were incubated
at 37C for 30 min. The sections were washed with distilled water
and immunoreactivitywas detectedwithdiaminobenzidine prior to
counterstaining with hematoxylin.
2.5. Sample preparation
Mice were anesthetized with diethyl ether, and the brains were
collected and weighed. Water (1 mL) was added to 0.1 g of brain
tissue, and the mixtures were homogenized in an ice bath. An
aliquot of 600 mL of ice-cold methanol was then added to 150 mL of
the homogenate, and the mixture was vortexed for 5 min followed
by centrifugation at 12,000g for 10 min at 4C. The supernatant was
transferred to another tube and evaporated to dryness at 30C
under a gentle stream of nitrogen. The dried residue was then
reconstituted in 100 mL of acetonitrile-water (2:98, v/v) and a 10-mL
aliquot was used in the UPLC/MS analysis.
2.6. Spectrum acquisition
Liquid chromatography was performed on a Waters Acquity
UPLC system (Waters Corp., Milford, MA, USA). Separation was
achieved with a Waters ethylene-bridged hybrid (BEH) C18 column
Table 1
Ultra performance liquid chromatography-MS gradient elution program
Time (min) %A (0.1% FA-water) %B (0.1% FA-acetonitrile)
Initial 98 2
2 92 8
4 60 40
17 12 88
18 0 100
21 98 2
FA ¼ formic acid.
Table 2
Effects of ginsenoside Rg1 (G-Rg1) and G-Rg2 on the escape latency of Alzheimer’s
disease (AD) mice In the Morris water maze test
Group
(n ¼ 10)
Training day
1 2 3 4 5
Control 59.9  0.7 34.0  6.1** 21.3  2.1** 18.6  3.3** 18.9  2.7**
AD model 58.1  2.8 59.9  0.9 48.5  5.6 50.4  4.1 41.3  6.3
G-Rg1 59.9  1.1 52.3  6.0 39.2  6.1 32.1  5.0** 27.1  4.9**
G-Rg2 59.9  1.2 42.2  5.7 34.1  5.2 30.6  4.9** 25.3  3.7*
* p < 0.05 versus AD model group (one-way analysis of variance).
** p < 0.01 versus AD model group (one-way analysis of variance).
AD, Alzheimer’s disease; G-Rg1, Ginsenside Rg1; G-Rg2, Ginsenside Rg2.
Fig. 1. Effects of Ginsenoside Rg1 (G-Rg1) and G-Rg2 on the performance of Alz-
heimer’s disease (AD) mice in the Morris water maze test. (A) Number of platform
crossings within 60 s and (B) time in the target quadrant were measured. Values
indicate mean  standard deviation (SD) [one-way analysis of variance followed by
Tukey’s multiple comparison test (n ¼ 10)]. *p < 0.05 versus AD model group,
**p < 0.01 versus AD model group. AD, Alzheimer’s disease; G-Rg1, Ginsenside Rg1; G-
Rg2, Ginsenside Rg2.
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mobile phase composed of water and acetonitrile with 0.1% formic
acid was performed at a ﬂow rate of 0.3 mL/min (Table 1).
Mass spectrometric detection was performed on a Micromass
Quattro Micro API mass spectrometer (Waters Corp.) with an
electrospray ionization interface and triple quadrupole mass
analyzer. The electrospray ionization source was set in the positive
mode. The following parameters were used: capillary voltage,
3.2 kV; cone voltage, 30 V; source temperature, 120C; and des-
olvation temperature, 300C. Nitrogen was used for desolvation
and as the cone gas at ﬂow rates of 600 L/h and 50 L/h, respectively.
The full scanmodewas used in a mass range of 100e1,000 amu. For
MS/MS, argonwas used as the collision gas, and the collision energy
was set according to the metabolite composition. NaCsI was used
for mass correction before the experiment was commenced. Data
were collected in centroid mode.
2.7. Statistical analysis
SPSS version 19.0 software (SPSS Inc., Chicago, IL, USA) was used
to analyze the data from the MWM test, which were evaluated by
the analysis of variance, followed by Tukey’s multiple comparison
test. The results are expressed as mean  standard deviation (SD),
and differences are considered statistically signiﬁcant at p < 0.05.
The UPLC/MS data from the brain samples were analyzed with
Markerlynx within Masslynx software version 4.1 (Waters Corp.).
The retention time andm/z were calculated for each peak. Principal
components analysis (PCA) was used to select distinct variables,
and Student t test was used to evaluate statistically signiﬁcant
differences between potential biomarkers (SPSS version19.0 soft-
ware; SPSS Inc.). Statistical signiﬁcance was accepted if p < 0.05.
2.8. Identiﬁcation of biomarkers
In positive product ion scan spectra, samples were analyzed and
low molecular weight metabolites were visible as chromatographic
peaks in the total ion chromatograms. Fragmentation patterns of
potential brain biomarkers were obtained from collision-induced
dissociation experiments. The biomarkers were identiﬁed by
comparing their retention time, mass value, and MS/MS fragmenta-
tion with the corresponding parameters of the reference standards
and available references. In addition, full scan mass spectra of these
metabolites were interpreted using biochemical databases including
theKyoto Encyclopedia ofGenes andGenomesdatabase (http://www.
genome.jp/kegg/), the Human Metabolome Database (http://www.
hmdb.ca/), and the Lipidomics Gateway (http://www.lipidmaps.org/).
3. Results
3.1. G-Rg1 and G-Rg2 improve the performance of APP/PS1 mice in
the MWM test
In the place navigation test, the average escape latency of the
mice in searching for the hidden underwater platform decreasedover the training days (Table 2). From Day 2 onwards, the escape
latencies among the ADmodel groupwere signiﬁcantly longer than
those of the normal control group (p < 0.01). G-Rg1 and G-Rg2
reduced the escape latencies on the last two training days
compared to the AD model group (p < 0.05). In the spatial explo-
ration test, the total time spent in the target quadrant and the
number of mice that exactly crossed the previous position of the
platform were clearly shorter and lower, respectively, in the AD
model groupmice than in the normal control groupmice (p< 0.01),
a trend that was reversed by treatment with G-Rg1 and G-Rg2 (G-
Rg1, p < 0.01; G-Rg2, p < 0.05). The effects of G-Rg1 and G-Rg2
treatment on the performance of the mice in the spatial probe trial
are shown in Fig. 1.
The MWM results show that the APP/PS1 mice were markedly
deﬁcient in cognitive function compared with age-matched C57BL/
J Ginseng Res 2016;40:9e17126J mice, which is consistent with previous studies [23]. Treatment
with G-Rg1 and G-Rg2 effectively improved cognitive function of
the mice that had declined due to AD.
3.2. G-Rg1 and G-Rg2 reduce Ab1-42 accumulation in APP/PS1 mice
In the immunohistochemistry study, no clear Ab depositions
were observed in the hippocampi of the normal control mice
(Fig. 2A). By contrast, marked morphological changes were
observed in the AD model mice: neurons were loosely organized
and darkly stained, and there were dark brown, scattered Ab de-
posits (Fig. 2B). In the G-Rg1 and G-Rg2 treated mice, the patho-
logical abnormalities observed in the APP/PS1 mice were gradually
ameliorated. Clear nucleoli and light brown, sparsely scattered Ab
deposits were visible (Figs. 2C, 2D). These results, combined with
the behavioral results discussed above, indicate that the impaired
cognitive function and increased hippocampal Ab depositions in
the APP/PS1micewere partly ameliorated by treatment with G-Rg1
and G-Rg2.
3.3. Metabolite proﬁles in AD
3.3.1. Method development and veriﬁcation
Ametabolomics studywas conducted to investigate the possible
mechanisms of action of G-Rg1 and G-Rg2 in the APP/PS1mice. TheFig. 2. Effects of Ginsenoside Rg1 (G-Rg1) and G-Rg2 on the histopathological changes in
disease (AD) model group; (C) G-Rg1 group; and (D) G-Rg2 group are shown at 100 magn
Ginsenside Rg2.preparation of brain samples for metabolic proﬁling analysis with
UPLC/MS involved a protein precipitation step to separate the low-
molecular-weight compounds and remove large amounts of pro-
teins that would otherwise interfere with the UPLC/MS analysis.
Quantitative information was obtained in the positive ion mode
rather than in the negative ion mode. Typical total ion chromato-
grams of brain samples from the normal control group (A), AD
model group (B), G-Rg1 group (C), and G-Rg2 group (D) are shown
in Fig. 3. The applied method was validated before the analysis of
the experimental samples by determining the precision, within-
day stability, and repeatability of sample preparation. The extrac-
ted ion chromatographic peaks of seven ions (m/z 132.2, 0.52 min;
m/z 120.1, 1.90 min; 710.5, 3.37 min; 346.7, 8.41 min; 502.3,
8.93 min; 374.1, 10.6 min; and 402.3, 12.88 min, in positive ion
mode) were distributed across different spectral regions, and the
retention times were selected to validate the method. The relative
SDs (RSDs) of the peak intensities and retention times for the
selected ions in the pooled brain sample were calculated. The
precision of injection was established with the continuous detec-
tion of ﬁve injections of the same sample. The RSDs ranged from
0.8% to 2.1% for the retention time and from 6.5% to 13.7% for the
peak intensity. The post-preparation stability of the sample was
tested by analyzing a sample left in the autosampler (maintained at
4C) for 4 h, 8 h, 12 h, and 24 h. The RSDs ranged from 3.5% to 11.7%
for the peak intensity and from 0.9% to 2.4% for the retention time.the hippocampus of APP/PS1 mice. (A) The normal control group; (B) the Alzheimer’s
iﬁcation. Scale bars ¼ 100 mm. AD, Alzheimer’s disease; G-Rg1, Ginsenside Rg1; G-Rg2,
Fig. 3. Typical total ion chromatograms of brain samples in positive mode. (A) The normal control group; (B) the Alzheimer’s disease (AD) model group; (C) Ginsenside Rg1 (G-Rg1)
group; and (D) G-Rg2 group. AD, Alzheimer’s disease; G-Rg1, Ginsenside Rg1; G-Rg2, Ginsenside Rg2.
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brain sample. The RSDs of the peak intensities ranged from 3.5% to
13.7% and those for the retention time ranged from 0.9% to 3.4%.
3.3.2. Metabolite proﬁling analysis
To determinewhether themetabolites in brain differed between
normal control and AD model mice, PCA, which is a classic unsu-
pervised method (no prior knowledge concerning groups or ten-
dencies within the data sets is necessary) of pattern recognition,
was used. In the PCA score, each point represented an individual
sample; the plot of PCA scores divided different brain samples into
blocks, suggesting changes in the metabolic proﬁles. Samples from
the normal control and AD model groups were clearly divided into
two classes (Fig. 4A), indicating that AD was successfully repro-
duced by this model and that speciﬁc biomarkers could distinguish
AD from normal control mice.
3.3.3. Biomarker identiﬁcation
In the PCA loading plots for the AD model and normal control
mice, the distance of an ion from the origin represents its inﬂuence
on PCA components (Fig. 4B). Ions in the plot were selected as
putative biomarkers (Table 3), andwere thosewith retention timee
m/z pairs of 0.82_136.8, 4.7_302.0, 6.4_274.2, 6.5_318.1, 10.0_454.0,
12.3_482.1, 10.2_480.1, 9.6_496.1, 10.1_518.1, 10.6_522.1, and
12.4_524.1. These biomarkers were compared with the data in the
literature [18,24,25] and biochemical databases, and further iden-
tiﬁed by comparing with corresponding standards according to
their retention times, m/z, and product ion scan spectra in positive
mode. For instance, the biomarker at m/z 496.1 contained four
major fragment ions, which are the same as those of LPC C 16:0
standard. The high-abundance fragment ions at m/z 104.1 and m/z
183.9 represent [HOCH2CH2N(CH3)3]þ and [H2O3PO-
CH2CH2N(CH3)3]þ, respectively, which identify the head group of
the phosphatidylcholine class of biomarkers. Another two major
fragment ions at m/z 258.1 (M-COC15H31þH)þ and m/z 478.5 (M-
H2O þ H)þ indicated that this biomarker is an LPC. The retention
time, mass value, and MS/MS fragmentation of this biomarker are
the same as those of LPC C 16:0 standard proved the metabolite is
LPC C 16:0. To evaluate changes in biomarker proﬁles, peak in-
tensities of putative biomarkers in the brains of AD and control
mice were compared (Fig. 5). The peak intensities of LPCs, dihy-
drosphingosine, hexadecasphinganine, and phytosphingosine werereduced and that of hypoxanthine was elevated in the brains of AD
mice compared to normal control mice (p < 0.05).
3.4. G-Rg1 and G-Rg2 treatment alters metabolite proﬁles of AD
mice
The PCA model was also used to determine whether G-Rg1 and
G-Rg2 affect the metabolite proﬁles of AD mice. According to the
PCA score plots (Fig. 6A) from processing dates of the normal
control, AD model, and G-Rg1 and G-Rg2 treated groups, samples
from the ginsenosides treated groups were separated from the AD
model group and were closer to the controls, suggesting that G-Rg1
and G-Rg2 treatment partly restored brain metabolites in AD mice
to near normal levels. Metabolites with altered levels were iden-
tiﬁed in the PCA loading plot (Fig. 6B); the peak intensity of hy-
poxanthine was lower, while those of dihydrosphingosine,
hexadecasphinganine, phytosphingosine, LPC C 13:0, LPC C 15:0,
LPC C 16:0, LPC C 18:0, LPC C 18:1, and LPC C 18:3 were higher in the
G-Rg1 group compared to the AD group (p < 0.05). G-Rg2 treat-
ment yielded similar results; the peak intensity of hypoxanthine
was lower, while those of dihydrosphingosine, hex-
adecasphinganine, LPC C 16:0, and LPC C 18:0 were higher in the G-
Rg2 compared to the AD group (p< 0.05; Fig. 7). These results show
that G-Rg1 and G-Rg2 can partly correct brainmetabolic alterations
in AD mice.
4. Discussion
Ginseng is one of the most widely used herbal medicines in
humans. In our study, a UPLC/MS-based metabolomics approach
was applied to the characterization of AD, and the protective effects
of G-Rg1 and G-Rg2 were investigated in APP/PS1 transgenic mice.
APP/PS1 mice are a reliable animal model for studies of AD pre-
vention and treatment because they exhibit neurodegenerative
changes in behavioral, biochemical, and histopathological aspects
that are similar to those observed in humans with AD [26,27]. The
cognitive dysfunctions and pathophysiological changes of APP/PS1
mice were alleviated by treatment with G-Rg1 and G-Rg2, which
provides evidence for the protective effects of G-Rg1 and G-Rg2
against AD. Moreover, 11 potential biomarkers related to AD were
changed in the brains of G-Rg1 and G-Rg2 treated mice. These
metabolites were associated with hypoxanthine, LPCs, and
Fig. 4. Principal components analysis (PCA) results derived from the ultra performance liquid chromatography tandem MS (UPLC/MS) of the Alzheimer’s disease (AD) model and
normal control mice brains in positive mode (n ¼ 10). (A) PCA score plot indicating the separation between two groups and (B) PCA loading plot indicating the potential biomarkers.
The variables are labeled with retention time and m/z. AD, Alzheimer’s disease.
J Ginseng Res 2016;40:9e1714sphingolipid metabolism, indicating the protective effects of G-Rg1
and G-Rg2 in AD are exerted through the modulation of these
pathways.
Hypoxanthine is a purine compound and is the principal purine
nucleobase involved in the salvage purine pathway in the brain [28].
Purinergic signaling plays an important role in the development of
neural diseases. Numerous studies have provided evidence for the
involvement of purine metabolites in the brains of patients with AD
[29,30], and this was also proved in the present study. In addition, a
deﬁciency in the activity of hypoxanthine-guanine phosphor-
ibosyltransferase, a hypoxanthine metabolic enzyme, has been
found inpatientswith neurodegenerative diseases. This could lead to
the accumulation of hypoxanthine [31]. It was reported that hypo-
xanthine enhanced acetylcholinesterase (AChE) activity in the hip-
pocampus and striatumof 15- and30-d-oldmice,when added to the
incubation medium [32]. AChE is associated with the pathophysi-
ology of AD. Constant stimulation of AChE activity might decrease
acetylcholine levels, in turn interfering with cholinergic trans-
mission. This is an essential neurotransmitter in the central nervous
system [33]. Therefore, AChE-related hypoxanthine metabolism
disorder is associated with memory deﬁcits. Moreover, hypoxan-
thine has also been reported to inhibit Naþ, Kþ-ATPase activity andTable 3
Potential biomarkers and change trends of them in different groups
Retention time (min) m/z Scan mode Quasi-molecular ion Meta
0.82 136.8 þ [MþH]þ Hypo
6.4 274.2 þ [MþH]þ Hexa
4.7 302.0 þ [MþH]þ Dihy
6.5 318.1 þ [MþH]þ Phyt
10.0 454.0 þ [MþH]þ LPC
10.2 480.1 þ [MþH]þ LPC
12.3 482.1 þ [MþH]þ LPC
9.6 496.1 þ [MþH]þ LPC
10.1 518.1 þ [MþH]þ LPC
10.6 522.1 þ [MþH]þ LPC
12.4 524.1 þ [MþH]þ LPC
AD, Alzheimer’s disease; G-Rg1, Ginsenside Rg1; G-Rg2, Ginsenside Rg2; LPC, lysophospinduces oxidative stress in rat striatum. Oxidative stress is a primary
event in the pathogenesis of AD and has been found to impair brain
memory ofmice [34]. From the above, abnormal brain hypoxanthine
concentration could be one of the factors leading to AD, and G-Rg1
and G-Rg2 may improve the metabolism of hypoxanthine and
decrease the concentration of hypoxanthine, which is associated
with AChE and oxidative stress, thus alleviating symptoms of AD.
LPCs are associated with the integrity of the neuronal mem-
brane structure and exert a diverse array of effects on cellular
functional activities. It is recognized that they can take part in
multiple neuronal pathways [35,36]. LPCs are related to lecithin
metabolism. Lecithin, an important component of cell membranes,
participates in the synthesis of the neurotransmitter acetylcholine
[37]. Moreover, impaired lecithin metabolism could result in le-
sions to the cell, which are involved in numerous human diseases,
particularly in the central nervous system because of its high lipid
content [38]. Thus, lower levels of LPCs were also observed in the
brains of ADmice compared to those of normal control mice. This is
consistent with previously published reports [39]. The brain is the
most lipid-rich tissue in mammals [40]. A disorder of lipid meta-
bolism in the brain is one of the factors leading to AD according to
the results. However, it was partly restored by treatment with G-bolites AD mice vs.
Controls
G-Rg1 treated
mice vs. AD mice
G-Rg2 treated
mice vs. AD mice
xanthine [ Y Y
decasphinganine Y [ [
drosphingosine Y [ [
osphingosine Y [
C 13:0 Y [
C 15:1 Y
C 15:0 Y [
C 16:0 Y [ [
C 18:3 Y [
C 18:1 Y [
C 18:0 Y [ [
hatidylcholine
Fig. 5. Peak intensities of putative potential biomarkers in the brains of the Alzheimer’s disease (AD) model and normal control groups. Identiﬁcation: 136.8, hypoxanthine; 274.2,
hexadecasphinganine; 302.0, dihydrosphingosine; 318.1, phytosphingosine; 454.0, lysophosphatidylcholine (LPC) C 13:0; 480.1, LPC C 15:1; 482.1, LPC C 15:0; 496.1, LPC C 16:0;
518.1, LPC C 18:3; 522.1, LPC C 18:1; and 524.1, LPC C 18:0. Values indicate mean  standard deviation (SD) [Student t test (n ¼ 10)]. * p < 0.05 versus normal control group. AD,
Alzheimer’s disease.
N. Li et al / Ginsenosides and Alzheimer’s disease 15Rg1 and G-Rg2, indicating that the therapeutic effects of G-Rg1 and
G-Rg2 are also connected with the modulation of impaired LPCs
metabolism, which is related to the neuronal membrane structure
and multiple neuronal pathways.
Dihydrosphingosine, hexadecasphinganine, and phytosphingo-
sine are classiﬁed as sphingolipids [41]. The central nervous system
contains large amounts of sphingolipids; their metabolites play not
only a structural role in biomembranes, but also act as second
messengers involved in the transduction of numerous cell signals
[42]. There is also strong evidence that cholesterol and sphingo-
myelin preferentially interact with each other in neuronal mem-
branes, and that this interaction has a direct effect on the structureFig. 6. Principal components analysis (PCA) results derived from the ultra performance li
normal control and ginsenosides treatment mice brains in positive mode (n ¼ 10). (A) PCA sc
the potential biomarkers. The variables are labeled with retention time and m/z. AD, Alzheand permeability of the cell membrane and second-messenger
systems [43]. In the brain, imbalances in the contents of various
classes of sphingolipids can result in neuronal dysfunction and
apoptosis of brain cells, ultimately leading to AD [44,45]. In our
previous study, we found changes in the sphingolipid levels in the
plasma of AD patients [19]. The results of this study proved that
disorders of sphingolipid levels are also observed in the brains of
AD mice, and indicated that G-Rg1 and G-Rg2 also take part in
sphingolipid metabolic pathways. G-Rg1 treatment increased the
levels of dihydrosphingosine, hexadecasphinganine, and phytos-
phingosine, whereas G-Rg2 treatment just increased the levels of
dihydrosphingosine and hexadecasphinganine. This difference,quid chromatography tandem MS (UPLC/MS) of the Alzheimer’s disease (AD) model,
ore plot indicating the separation among all the groups; (B) PCA loading plot indicating
imer’s disease; G-Rg1, Ginsenside Rg1; G-Rg2, Ginsenside Rg2.
Fig. 7. Peak intensities of potential biomarkers in the brains of Alzheimer’s disease (AD) model, normal control and ginsenosides treatment groups. Identiﬁcation: 136.8, hypo-
xanthine; 274.2, hexadecasphinganine; 302.0, dihydrosphingosine; 318.1, phytosphingosine; 454.0, lysophosphatidylcholine (LPC) C 13:0; 480.1, LPC C 15:1; 482.1, LPC C 15:0; 496.1,
LPC C 16:0; 518.1, LPC C 18:3; 522.1, LPC C 18:1; and 524.1, LPC C 18:0. Values indicate mean  standard deviation (SD) [Student t test (n ¼ 10)]. * p< 0.05 versus AD model group. AD,
Alzheimer’s disease; G-Rg1, Ginsenside Rg1; G-Rg2, Ginsenside Rg2.
J Ginseng Res 2016;40:9e1716combinedwith LPCsmetabolism results, shows that G-Rg1 restored
more AD-related metabolites to near normal levels than G-Rg2.
In summary, G-Rg1 and G-Rg2 treatment can partly restore
hypoxanthine, LPCs, and sphingolipid metabolism in the brains of
AD mice based on metabolomics results. To our knowledge, this is
the ﬁrst retrospective study using UPLC/MS to biochemically proﬁle
the brain metabolic pathways affected by G-Rg1 and G-Rg2 in AD
mice. It may contribute to our understanding of the biochemical
mechanisms involved in this effect.5. Conclusion
A brain metabolomics approach, combined with MWM and
immunohistochemistry, was used to identify metabolic changes in
the brains of ginsenoside treated mice and to evaluate the effects of
G-Rg1 and G-Rg2 on AD. The cognitive dysfunctions and patho-
physiological changes in APP/PS1 mice were alleviated by treat-
ment with G-Rg1 or G-Rg2. A total of 11 metabolites related to the
metabolism of sphingolipids, hypoxanthine, or lecithin were iden-
tiﬁed in the brains of ADmice. Treatmentwith G-Rg1 or G-Rg2 both
inﬂuenced sphingolipid, hypoxanthine, and lecithin metabolism
pathways. These results providemolecular evidence for the efﬁcacy
of these ginsenosides in AD treatment.Conﬂicts of interest
The authors declare no conﬂicts of interest.
Acknowledgments
Thanks to Yingge Gong, Pengyi Hou, and Can Xu for technical
assistance. This study was supported by the National Science
Foundation of China grant number 81203002 and Shenyang Sci-
ence and Technology Program number F12-193-9-22.References
[1] Inoue K, Tsutsui H, Akatsu H, Hashizume Y, Matsukawa N, Yamamoto T,
Toyo’oka T. Metabolic proﬁling of Alzheimer’s disease brains. Sci Rep 2013;3:
2364e72.
[2] Wan W, Chen H, Li Y. The potential mechanisms of Abeta-receptor for
advanced glycation end-products interaction disrupting tight junctions of the
blood-brain barrier in Alzheimer’s disease. Int J Neurosci 2014;124:75e81.
[3] Pratico D. Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal.
Trends Pharmacol Sci 2008;29:609e15.
[4] Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS. Multi-faced neuroprotective
effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim Biophys
Acta 2012;1822:286e92.
[5] Tan X, Gu J, Zhao B, Wang S, Yuan J, Wang C, Chen J, Liu J, Feng L, Jia X. Ginseng
improves cognitive deﬁcit via the RAGE/NF-kB pathway in advanced glycation
end product-induced rats. J Ginseng Res 2014;9:1e9.
[6] Liu L, Huang J, Hu X, Li K, Sun C. Simultaneous determination of ginsenoside
(G-Re, G-Rg1, G-Rg2, G-F1, G-Rh1) and protopanaxatriol in human plasma and
urine by LCeMS/MS and its application in a pharmacokinetics study of G-Re in
volunteers. J Chromatogr B 2011;879:2011e7.
[7] Li N, Liu B, Dluzen DE, Jin Y. Protective effects of ginsenoside Rg2 against
glutamate-induced neurotoxicity in PC12 cells. J Ethnopharmacol 2007;111:
458e63.
[8] Kim JH. Cardiovascular diseases and Panax ginseng: a review on molec-
ular mechanisms and medical applications. J Ginseng Res 2012;36:16e
26.
[9] Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimer’s am-
yloid peptide after oral administration of ginsenosides. Faseb J 2006;20:1269e
71.
[10] Shi C, Zheng DD, Fang L, Wu F, Kwong WH, Xu J. Ginsenoside Rg1 promotes
nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/
ERK and PI3K/Akt. Biochim Biophys Acta 2012;1820:453e60.
[11] Kim HJ, Kim P, Shin CY. A comprehensive review of the therapeutic and
pharmacological effects of ginseng and ginsenosides in central nervous sys-
tem. J Ginseng Res 2013;37:8e29.
[12] Nicholson JK, Lindon JC, Holmes E. ’Metabonomics’: understanding the
metabolic responses of living systems to pathophysiological stimuli via
multivariate statistical analysis of biological NMR spectroscopic data. Xen-
obiotica 1999;29:1181e9.
[13] Lan MJ, McLoughlin GA, Grifﬁn JL, Tsang TM, Huang JTJ, Yuan P, Manji H,
Holmes E, Bahn S. Metabonomic analysis identiﬁes molecular changes asso-
ciated with the pathophysiology and drug treatment of bipolar disorder. Mol
Psychiatr 2009;14:269e79.
[14] Want EJ, Nordströ m A, Morita H, Siuzdak G. From exogenous to endogenous.
the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res
2007;6:459e68.
N. Li et al / Ginsenosides and Alzheimer’s disease 17[15] Zheng X, Kang A, Dai C, Liang Y, Xie T, Xie L, Peng Y, Wang G, Hao H. Quan-
titative analysis of neurochemical panel in rat brain and plasma by liquid
chromatography-tandem mass spectrometry. Anal Chem 2012;84:10044e51.
[16] Wang X, Yang B, Sun H, Zhang A. Pattern recognition approaches and
computational systems tools for ultra performance liquid chromatography-
mass spectrometry-based comprehensive metabolomic proﬁling and path-
ways analysis of biological data sets. Anal Chem 2012;84:428e39.
[17] Dai W, Wei C, Kong H, Jia Z, Han J, Zhang F, Wu Z, Gu Y, Chen S, Gu Q, et al.
Effect of the traditional Chinese medicine tongxinluo on endothelial
dysfunction rats studied by using urinary metabonomics based on liquid
chromatography-mass spectrometry. J Pharmaceut Biomed 2011;56:86e92.
[18] Li NJ, Liu WT, Li W, Li SQ, Chen XH, Bi KS, He P. Plasma metabolic proﬁling of
Alzheimer’s disease by liquid chromatography/mass spectrometry. Clin Bio-
chem 2010;43:992e7.
[19] Liu Y, Li NJ, Zhou L, Li Q, Li W. Plasma metabolic proﬁling of mild cognitive
impairment and Alzheimer’s disease using liquid chromatography/mass
spectrometry. Cent Nerv Syst Agents Med Chem 2014;14:113e20.
[20] Li X, Zhao X, Xu X, Mao X, Liu Z, Li H, Guo L, Bi K, Jia Y. Schisantherin A re-
covers Abeta-induced neurodegeneration with cognitive decline in mice.
Physiol Behav 2014;132:10e6.
[21] Liu Z, Zhao X, Liu B, Liu AJ, Li H, Mao X, Wu B, Bi KS, Jia Y, Jujuboside A. a
neuroprotective agent from semen Ziziphi Spinosae ameliorates behavioral
disorders of the dementia mouse model induced by Abeta 1-42. Eur J Phar-
macol 2014;738:206e13.
[22] Li Y, Ma Y, Zong L-X, Xing X-N, Guo R, Jiang T-Z, Sha S, Liu L, Cao Y-P. Intra-
nasal inoculation with an adenovirus vaccine encoding ten repeats of Ab3-10
reduces AD-like pathology and cognitive impairment in Tg-APPswe/
PSEN1dE9 mice. J Neuroimmunol 2012;249:16e26.
[23] Ma Y, Li Y, Zong LX, Xing XN, Zhang WG, Cao YP. Improving memory and
decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with Abeta3-
10 repeat fragment plasmid by reducing Abeta deposition and inﬂammatory
response. Brain Res 2011;1400:112e24.
[24] Yin P, Mohemaiti P, Chen J, Zhao X, Lu X, Yimiti A, Upur H, Xu G. Serum
metabolic proﬁling of abnormal savda by liquid chromatography/mass spec-
trometry. J Chromatogr B 2008;871:322e7.
[25] Huo T, Cai S, Lu X, Sha Y, Yu M, Li F. Metabonomic study of biochemical
changes in the serum of type 2 diabetes mellitus patients after the treatment
of metformin hydrochloride. J Pharmaceut Biomed 2009;49:976e82.
[26] Zhang H, Gao Y, Qiao PF, Zhao FL, Yan Y. Fenoﬁbrate reduces amyloidogenic
processing of APP in APP/PS1transgenic mice via PPAR- a/PI3-K pathway. Int J
Dev Neurosci 2014;38:223e31.
[27] Kim HY, Kim HV, Yoon JH, Kang BR, Cho SM, Lee S, Kim JY, Kim JW, Cho Y,
Woo J, et al. Taurine in drinking water recovers learning and memory in the
adult APP/PS1 mouse model of Alzheimer’s disease. Sci Rep 2014;4:7467e73.
[28] Bavaresco CS, Chiarani F, Matte C, Wajner M, Netto CA, de Souza Wyse AT.
Effect of hypoxanthine on Naþ, Kþ-ATPase activity and some parameters of
oxidative stress in rat striatum. Brain Res 2005;1041:198e204.
[29] González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL. Metab-
olomic screening of regional brain alterations in the APP/PS1 transgenicmodel of Alzheimer’s disease by direct infusion mass spectrometry.
J Pharmaceut Biomed 2015;102:425e35.
[30] Xiang Z, Xu M, Liao M, Jiang Y, Jiang Q, Feng R, Zhang L, Ma G, Wang G, Chen Z,
et al. Integrating genome-wide association study and brain expression data
highlights cell adhesion molecules and purine metabolism in Alzheimer’s
disease. Mol Neurobiol 2014;09:1e8.
[31] Bavaresco CS, Chiarani F, Kolling J, Netto CA, Souza Wyse ATD. Biochemical
effects of pretreatment with vitamins E and C in rats submitted to intrastriatal
hypoxanthine administration. Neurochem Int 2008;52:1276e83.
[32] Wamser MN, Leite EF, Ferreira VV, Delwing-de Lima D, da Cruz JGP, Wyse ATS,
Delwing-Dal Magro D. Effect of hypoxanthine, antioxidants and allopurinol on
cholinesterase activities in rats. J Neural Transm 2013;120:1359e67.
[33] Melo JB, Agostinho P, Oliveira CR. Involvement of oxidative stress in the
enhancement of acetylcholinesterase activity induced by amyloid beta-pep-
tide. Neurosci Res 2003;45:117e27.
[34] Bavaresco CS, Chiarani F, Duringon E, Ferro MM, Cunha CD, Netto CA,
Wyse AT. Intrastriatal injection of hypoxanthine reduces striatal serotonin
content and impairs spatial memory performance in rats. Metab Brain Dis
2007;22:67e76.
[35] Gonzalez-Dominguez R, García-Barrera T, Gomez-Ariza JL. Combination of
metabolomic and phospholipid-proﬁling approaches for the study of Alz-
heimer’s disease. J Proteomics 2014;104:37e47.
[36] Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA. Glycerophospholipids
and glycerophospholipid-derived lipid mediators: a complex meshwork in
Alzheimer’s disease pathology. Prog Lipid Res 2011;50:313e30.
[37] Klein J. Membrane breakdown in acute and chronic neurodegeneration: focus
on choline-containing phospholipids. J Neural Transm 2000;107:1027e63.
[38] Vestergaard MC, Morita M, Hamada T, Takagi M. Membrane fusion and ve-
sicular transformation induced by Alzheimer’s amyloid beta. Biochim Biophys
Acta 2013;1828:1314e21.
[39] Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui G,
Paolo GD. Comparative lipidomic analysis of mouse and human brain with
Alzheimer disease. J Biol Chem 2012;287:2678e88.
[40] Axelsen PH, Murphy RC. Quantitative analysis of phospholipids containing
arachidonate and docosahexaenoate chains in microdissected regions of
mouse brain. J Lipid Res 2010;51:660e71.
[41] Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional
sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim
Biophys Acta 2010;1801:878e86.
[42] Alessenko AV. The potential role for sphingolipids in neuropathogenesis of
Alzheimer’s disease. Biomed Khim 2013;59:25e50.
[43] Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway
in ceramide metabolism and signaling. Cell Signal 2008;20:1010e8.
[44] Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC.
Serum sphingomyelins and ceramides are early predictors of memory
impairment. Neurobiol Aging 2010;31:17e24.
[45] Mielke MM, Lyketsos CG. Alterations of the sphingolipid pathway in Alz-
heimer’s disease: new biomarkers and treatment targets? Neuromol Med
2010;12:331e40.
